Evidence map›Paper›PMID 38189332›Full record

ArticleMicrobiology spectrum2024

Longitudinal patterns in indeterminate HIV rapid antibody test results: a population-based, prospective cohort study.

Joanne H Hunt, George Mwinnyaa, Eshan U Patel, M Kate Grabowski, Joseph Kagaayi, Ronald H Gray, Joseph Ssekasanvu, Maria J Wawer, Godfrey Kigozi, Larry W Chang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Joanne H Hunt *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-6230-841X
George Mwinnyaa *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Eshan U PatelDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-2174-5004
M Kate GrabowskiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Joseph KagaayiRakai Health Sciences Program, Kalisizo, Uganda.
Ronald H GrayDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Joseph SsekasanvuRakai Health Sciences Program, Kalisizo, Uganda.
Maria J WawerDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Godfrey KigoziRakai Health Sciences Program, Kalisizo, Uganda.
Larry W ChangDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Sarah KalibbalaRakai Health Sciences Program, Kalisizo, Uganda.
Margaret NakalanziRakai Health Sciences Program, Kalisizo, Uganda.
Anthony NdyanaboRakai Health Sciences Program, Kalisizo, Uganda.
Thomas C QuinnLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
David SerwaddaRakai Health Sciences Program, Kalisizo, Uganda.
Steven J ReynoldsLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Ronald M GaliwangoRakai Health Sciences Program, Kalisizo, Uganda.
Oliver LaeyendeckerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-6429-4760

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Circumcision: HIV/STIs and behaviors in a RCT and post-RCT surveillance; RakaiU01AI075115 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2007 to 2011
$9.3M
ARV effects on HIV epidemiology &behaviors Rakai UgandaR01HD050180 · NICHD · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2005 to 2009
$7.8M
Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
Methods for Reducing Spatial Uncertainty and Bias in Disease SurveillanceR01AI102939 · NIAID · JOHNS HOPKINS UNIVERSITY · PI LESSLER, JUSTIN · 2013 to 2017
$4.6M
Enhanced Provision of Male Circumcision for HIV Prevention, Rakai, UgandaU01AI100031 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2012 to 2014
$3.2M
CHWs, mHealth, and Combination HIV Prevention in a Hotspot: A Randomized TrialR01MH107275 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2015 to 2019
$2.7M
Hard-to-Reach Populations: Implications for Ending the AIDS EpidemicR01AI143333 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2019 to 2022
$2.4M
HIV Incidence, Transmission Dynamics and Combination HIV Prevention: Rakai UgandaR01AI110324 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2014 to 2016
$2.4M
The Problem With Male Sexual/Repro Health:Qualitative/Quantitative Study, UgandaR01HD070769 · NICHD · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2011 to 2013
$1.4M
NIAID NIH HHS K01 AI125086NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI102939NIAID NIH HHS R01 AI110324NIAID NIH HHS R01 AI143333NIAID NIH HHS T32 AI102623NIAID NIH HHS U01 AI075115NIAID NIH HHS U01 AI100031NIAID NIH HHS UM1 AI068613NICHD NIH HHS R01 HD050180NICHD NIH HHS R01 HD070769NIDA NIH HHS F31 DA054849NIMH NIH HHS R01 MH107275
6 · The paper itself

Abstract

Rapid HIV tests are critical to HIV surveillance and universal testing and treatment programs. We assessed longitudinal patterns in indeterminate HIV rapid test results in an African population-based cohort. Prospective HIV rapid antibody test results, defined by two parallel rapid tests, among participants aged 15-49 years from three survey rounds of the Rakai Community Cohort Study, Uganda, from 2013 to 2018, were assessed. An indeterminate result was defined as any weak positive result or when one test was negative and the other was positive. A total of 31,405 participants contributed 54,459 person-visits, with 15,713 participants contributing multiple visits and 7,351 participants contributing 3 visits. The prevalence of indeterminate results was 2.7% (1,490/54,469). Of the participants with multiple visits who initially tested indeterminate (

Indexed as

HIV InfectionsCohort StudiesFemaleHIV TestingHumansLongitudinal StudiesMaleProspective StudiesUgandaHIV diagnosticsindeterminatepoint of care testingrapid testserology

Identifiers

PMID38189332
PMCPMC10845946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.